William Blair Has Bullish Forecast for CVRx FY2024 Earnings

CVRx, Inc. (NASDAQ:CVRX) – Investment analysts at William Blair upped their FY2024 EPS estimates for CVRx in a research note issued to investors on Tuesday, January 14th. William Blair analyst M. Andrew now expects that the company will post earnings per share of ($2.62) for the year, up from their previous estimate of ($2.65). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.62) per share. William Blair also issued estimates for CVRx’s Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.64) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.08) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.82) EPS.

CVRx (NASDAQ:CVRX) last released its earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.12). CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. The company had revenue of $13.37 million during the quarter, compared to analyst estimates of $13.28 million. During the same period in the previous year, the firm posted ($0.43) EPS.

CVRX has been the subject of a number of other research reports. Lake Street Capital lifted their price objective on CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price objective (up previously from $13.00) on shares of CVRx in a research report on Wednesday, October 30th. Craig Hallum raised their price objective on CVRx from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Canaccord Genuity Group boosted their target price on shares of CVRx from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $14.00 price objective on shares of CVRx in a research note on Wednesday, October 23rd. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, CVRx currently has a consensus rating of “Moderate Buy” and an average price target of $16.67.

CVRx Trading Up 5.3 %

Shares of CVRX stock opened at $17.00 on Thursday. CVRx has a fifty-two week low of $6.40 and a fifty-two week high of $29.23. The company has a quick ratio of 10.23, a current ratio of 11.32 and a debt-to-equity ratio of 0.76. The business has a fifty day simple moving average of $14.01 and a 200-day simple moving average of $11.00. The stock has a market cap of $412.49 million, a P/E ratio of -6.30 and a beta of 1.26.

Institutional Investors Weigh In On CVRx

Hedge funds have recently modified their holdings of the business. Barclays PLC increased its stake in CVRx by 312.5% in the third quarter. Barclays PLC now owns 19,067 shares of the company’s stock valued at $169,000 after acquiring an additional 14,445 shares during the period. Geode Capital Management LLC boosted its stake in shares of CVRx by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock valued at $2,600,000 after purchasing an additional 6,443 shares during the last quarter. XTX Topco Ltd bought a new stake in CVRx in the third quarter valued at about $150,000. Jane Street Group LLC boosted its position in shares of CVRx by 36.1% during the third quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after purchasing an additional 5,053 shares in the last quarter. Finally, State Street Corp raised its holdings in CVRx by 11.4% during the 3rd quarter. State Street Corp now owns 264,733 shares of the company’s stock worth $2,332,000 after buying an additional 27,071 shares during the period. 75.27% of the stock is owned by institutional investors.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.